secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001564590-23-006505
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology closes $5.75M public offering to fund THIO trials and R&D
----------------------------------------------------------------------------

- Gross proceeds of ~$5.75M from 2,555,500 shares at $2.25/share, including full over-allotment exercise.
- Net proceeds of ~$5.1M after underwriting discounts and expenses; intended for THIO trials and telomere compound development.
- Representative's warrants to purchase up to 127,775 shares at $2.8125/share, exercisable from Oct 2023 to Apr 2028.
- ThinkEquity acted as sole book-running manager for the offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/0001564590-23-006505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/maia-8k_20230424.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-006505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer